Status:
RECRUITING
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Lead Sponsor:
Immune Oncology Research Institute
Conditions:
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Eligibility:
All Genders
Brief Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal the...
Detailed Description
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid le...
Eligibility Criteria
Inclusion
- Diagnosis of BPDCN
- Signed informed consent form for prospective patients
Exclusion
- \-
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2032
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05430971
Start Date
July 1 2022
End Date
July 1 2032
Last Update
October 2 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, United States, 33136
2
Moffitt Cancer Center
Tampa, Florida, United States, 33612
3
Seattle Children's Cancer and Blood Disorders Center
Seattle, Washington, United States, 98145
4
Hematology Center named after prof. R. Yeolyan
Yerevan, Yerevan, Armenia, 0014